Dr Komal Aslam,Dr Fahad Naeem, Dr Syeda Kanwal Zameer
The most common functional gastrointestinal disorder with approximately 10 percent prevalence is known as Functional dyspepsia. Functional dyspepsia has remarkably disturbed the health care system. The statics indicates that almost 9.5 billion US dollar ascribable to the diagnosis of functional dyspepsia. Many studies reported that functional dyspepsia has linked with reduced quality of life. Two groups were made group A with 12 weeks trial of amitriptyline, escitalopram, and matching placebo in patients with FD. Age ranges from 18-65 both male and female were eligible the study. An informed consent was obtained from the participants after explaining the purpose of the study. PDS (post prandial fullness syndrome) was defined as having indigestion, feeling of fullness and early satiety two or more days per week. EPS (epigastric pain syndrome) was defined as weekly, or more frequent, epigastric pain or burning. The results have demonstrated that TCAs (amitriptyline) can be used to improve global FD symptoms. It will not induce or aggravate the delaying gastric emptying in FD patients.